Alterations to the pharmacokinetics of sedative and analgesic drugs and their metabolites (morphine - morphine 3 glucorunide, morphine 6 glucuronide, midazolam - 1 and 4 hydroxy midazolam, fentanyl - norfentanyl, dexmedetiomedine, propofol, thiopentone) in critically ill patients receiving ECMO. Clinical Trials

1 recruitingLast updated: May 13, 2026

There is 1 actively recruiting alterations to the pharmacokinetics of sedative and analgesic drugs and their metabolites (morphine - morphine 3 glucorunide, morphine 6 glucuronide, midazolam - 1 and 4 hydroxy midazolam, fentanyl - norfentanyl, dexmedetiomedine, propofol, thiopentone) in critically ill patients receiving ecmo. clinical trial across 2 countries. Updated daily from ClinicalTrials.gov.


Alterations to the pharmacokinetics of sedative and analgesic drugs and their metabolites (morphine - morphine 3 glucorunide, morphine 6 glucuronide, midazolam - 1 and 4 hydroxy midazolam, fentanyl - norfentanyl, dexmedetiomedine, propofol, thiopentone) in critically ill patients receiving ECMO. Trials at a Glance

1 actively recruiting trial for alterations to the pharmacokinetics of sedative and analgesic drugs and their metabolites (morphine - morphine 3 glucorunide, morphine 6 glucuronide, midazolam - 1 and 4 hydroxy midazolam, fentanyl - norfentanyl, dexmedetiomedine, propofol, thiopentone) in critically ill patients receiving ecmo. is listed on ClinicalTrialsFinder. Lead sponsors running alterations to the pharmacokinetics of sedative and analgesic drugs and their metabolites (morphine - morphine 3 glucorunide, morphine 6 glucuronide, midazolam - 1 and 4 hydroxy midazolam, fentanyl - norfentanyl, dexmedetiomedine, propofol, thiopentone) in critically ill patients receiving ecmo. studies include Critical Care Research Group.

About Alterations to the pharmacokinetics of sedative and analgesic drugs and their metabolites (morphine - morphine 3 glucorunide, morphine 6 glucuronide, midazolam - 1 and 4 hydroxy midazolam, fentanyl - norfentanyl, dexmedetiomedine, propofol, thiopentone) in critically ill patients receiving ECMO. Clinical Trials

Looking for clinical trials for Alterations to the pharmacokinetics of sedative and analgesic drugs and their metabolites (morphine - morphine 3 glucorunide, morphine 6 glucuronide, midazolam - 1 and 4 hydroxy midazolam, fentanyl - norfentanyl, dexmedetiomedine, propofol, thiopentone) in critically ill patients receiving ECMO.? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Alterations to the pharmacokinetics of sedative and analgesic drugs and their metabolites (morphine - morphine 3 glucorunide, morphine 6 glucuronide, midazolam - 1 and 4 hydroxy midazolam, fentanyl - norfentanyl, dexmedetiomedine, propofol, thiopentone) in critically ill patients receiving ECMO. trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Alterations to the pharmacokinetics of sedative and analgesic drugs and their metabolites (morphine - morphine 3 glucorunide, morphine 6 glucuronide, midazolam - 1 and 4 hydroxy midazolam, fentanyl - norfentanyl, dexmedetiomedine, propofol, thiopentone) in critically ill patients receiving ECMO. clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.